Program
DA-007
A development code.
Its studies are mostly in Alopecia, led by Applied Biology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Applied Biology | 11 open or running | phase 3since Jan 1, 2025 | Jan 1, 2025 | Mar 11, 2028phase 3 · NCT06762548 |
Also a collaborator on its studies: Daniel Alain and Follea International.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 1, 2025First study: phase 3 study in Chemotherapy Induced AlopeciaFirst studyNCT06762548 · 140 planned · Italy
- Nov 2, 2026Primary completion moved from 2026-09-11 to 2028-03-11Date moved laterphase 3 · +18 months · NCT06762548
Ahead
- Mar 11, 2028Primary completion: phase 3 study in Chemotherapy Induced AlopeciaNCT06762548
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06762548Chemotherapy Induced Alopecia · Italy | 3 | Not yet recruiting | Mar 11, 2028 | 140 |
How it is read
Names in the registry
- “DA-007”, 1 entry
Codes read as this program: DA007.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.